The potential reclassification of cannabinoids, particularly at the federal level, is generating considerable buzz within the market. A shift away from Schedule I status, often regarded as outdated and hindering progress, could unlock significant possibilities for companies. Reduced regulatory restrictions, alongside greater access to banking and f